leadf
logo-loader
viewAdmiralty Resources Ltd

Admiralty Resources appoints new chairman

boardroom_350_51f75145bfea7.jpg

Admiralty Resources (ASX: ADY) has appointed David Karpin as its chairman and non-executive director.

Karpin has previously held positions with the Rio Tinto Group, Argyle Diamonds, Royal Melbourne Hospital, Warrnambool Cheese and Butter, Racing Victoria and Melbourne Business School.
 
He was formerly an Adjunct Professor of Management at Australian National University and led the Australian Government Task Force on Leadership and Management Skills from 1992 to 1995.

Karpin was made a Member of the Order of Australia in 1996.

In May this year, Admiralty delivered a positive Pre-Feasibility Study for its Mariposa magnetite iron ore project, which is located in the Atacama region of Chile, and is around 20 kilometres south of Vallenar.

Key takeaways include a 49.1% post-tax internal rate of return, a 2.25 year payback on a $65.5 million capital investment.

This is based on a Resource of 66.6 million tonnes at 35.6% iron using a cut-off of 25% iron that provides for a 12 year Life of Mine and operational cost for final product CFR China ports of $89.10 per tonne.

Mariposa also has a post-tax Net Present Value (NPV) of $211 million at a 8% discount rate at World Bank forecasted long-term iron prices with an average of $141/tonne of the final product at 62% iron.

The PFS was completed by Redco Mining Consultants (REDCO) over the project. It also found that changing the parameters to use a current prevailing iron ore price of $128.50/tonne CFR China still yielded an attractive IRR of 41.37%, a 2.5 year payback and a post-tax NPV of $148 million.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Admiralty Resources Ltd

Price: 0.013 AUD

ASX:ADY
Market: ASX
Market Cap: $15.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma presents at the Proactive One2One virtual conference

Amryt Pharma's LON:AMYT) Rory Nealon presents at the Proactive One2One virtual conference. Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of people with rare and orphan diseases. The company...

7 hours, 55 minutes ago

2 min read